glp-1 grocery impact news GLP-1s may shrink appetite. But the bigger question is: What happens to the basket? Less food noise can mean fewer impulse buys, smaller portions, and better choices Retailers across the country are

While rebates may still be unavailable in 2027 for employers that cover GLP-1s only for obesity-related conditions but not for the broader weight loss indication, the potential impact may be smaller with a lower list price

Phase 3 trials with TransCon CNP in achondroplasia and hypochondroplasia

1 Beyond diabetes and obesity Cardiovascular disease In March 2024, the US Food and Drug Administration (FDA) approved Wegovy (semaglutide) for adults with cardiovascular disease (CVD) and either obesity and overweight to reduce the risk of cardiovascular death, heart attack, and stroke

Dissolvable Strips: Easy-to-use oral strips that melt quickly for convenience